Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Study Of Oral CP-690550 As A Maintenance Therapy For Ulcerative Colitis


A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral CP-690,550 As A Maintenance Therapy In Subjects With Ulcerative Colitis




The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis (UC). The study proposes to assess whether compared to placebo, CP 690,550 maintenance therapy more effectively achieves mucosal healing and improves quality of life in subjects with UC.The study proposes to assess CP 690,550 pharmacokinetic exposure during maintenance therapy in subjects over the age of 18 years with UC.

Study Status: Recruiting


Condition Intervention Phase
Ulcerative Colitis Drug: Placebo
Drug: CP690,550
Drug: CP690,550
Phase 3

Verified by Pfizer January, 2014

Sponsored by: Pfizer
Information provided by: Pfizer identifier: NCT01458574

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Pfizer Call Center., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site